Research Analysts Offer Predictions for enGene Q4 Earnings

Key Points

• HC Wainwright raised its Q4 2025 earnings per share estimate for enGene to ($0.48), up from the previous estimate of ($0.54), while maintaining a "Buy" rating and a price target of $25.00.
• enGene's recent earnings report indicated a per share loss of ($0.51), slightly below the consensus estimate of ($0.48).
• Currently, enGene has attracted significant institutional interest, with approximately 64.16% of its shares held by institutional investors and hedge funds.

enGene Holdings Inc. (NASDAQ:ENGN - Free Report) - Stock analysts at HC Wainwright raised their Q4 2025 earnings per share estimates for enGene in a report issued on Monday, September 8th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings of ($0.48) per share for the quarter, up from their prior estimate of ($0.54). HC Wainwright has a "Buy" rating and a $25.00 price objective on the stock. The consensus estimate for enGene's current full-year earnings is ($1.56) per share.

enGene (NASDAQ:ENGN - Get Free Report) last posted its quarterly earnings data on Thursday, September 11th. The company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.06).

Separately, Morgan Stanley reduced their price target on enGene from $19.00 to $18.00 and set an "overweight" rating for the company in a research report on Friday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $21.00.

enGene Stock Up 0.4%

Shares of ENGN stock traded up $0.03 on Thursday, hitting $6.00. 34,590 shares of the stock were exchanged, compared to its average volume of 101,233. The company has a current ratio of 10.34, a quick ratio of 10.34 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $306.37 million, a P/E ratio of -3.16 and a beta of -0.39. The business has a 50-day moving average of $4.17 and a 200 day moving average of $4.11. enGene has a fifty-two week low of $2.65 and a fifty-two week high of $11.00.

Hedge Funds Weigh In On enGene

Large investors have recently made changes to their positions in the company. Cresset Asset Management LLC bought a new position in shares of enGene during the second quarter worth approximately $36,000. Paloma Partners Management Co bought a new position in shares of enGene during the second quarter worth approximately $38,000. Jane Street Group LLC bought a new position in shares of enGene during the fourth quarter worth approximately $93,000. Toronto Dominion Bank bought a new position in shares of enGene during the fourth quarter worth approximately $97,000. Finally, Cubist Systematic Strategies LLC increased its stake in shares of enGene by 15.7% during the fourth quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company's stock worth $102,000 after purchasing an additional 2,080 shares during the period. Institutional investors own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.